<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report on a patient with genetically proven <z:e sem="disease" ids="C0024408" disease_type="Disease or Syndrome" abbrv="MJD|SCA3">Machado-Joseph Disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e>) presenting with signs indistinguishable from <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>), including <z:chebi fb="0" ids="15765">levodopa</z:chebi> response and typical <z:chebi fb="0" ids="15765">levodopa</z:chebi>-induced motor fluctuations </plain></SENT>
<SENT sid="1" pm="."><plain>Only after 10 years of prolonged benefit from <z:chebi fb="0" ids="15765">levodopa</z:chebi> and different <z:chebi fb="0" ids="51065">dopamine agonists</z:chebi> (<z:mp ids='MP_0000273'>DA</z:mp>), the patient developed <z:hpo ids='HP_0001251'>cerebellar ataxia</z:hpo> and pyramidal signs </plain></SENT>
<SENT sid="2" pm="."><plain>Preferential D3-receptor-stimulating <z:chebi fb="0" ids="51065">dopamine agonists</z:chebi> especially showed a benefit at the time, when D2 receptor binding was reduced in IBZM SPECT </plain></SENT>
<SENT sid="3" pm="."><plain>This is the first report of a meaningful response to <z:mp ids='MP_0000273'>DA</z:mp> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> </plain></SENT>
</text></document>